JP2014510052A - 細胞外基質タンパク質合成を活性化する新規ペプチドおよびそれを含有する化粧料組成物 - Google Patents
細胞外基質タンパク質合成を活性化する新規ペプチドおよびそれを含有する化粧料組成物 Download PDFInfo
- Publication number
- JP2014510052A JP2014510052A JP2013553980A JP2013553980A JP2014510052A JP 2014510052 A JP2014510052 A JP 2014510052A JP 2013553980 A JP2013553980 A JP 2013553980A JP 2013553980 A JP2013553980 A JP 2013553980A JP 2014510052 A JP2014510052 A JP 2014510052A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- skin
- pro
- gly
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 15
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 15
- 238000001243 protein synthesis Methods 0.000 title claims abstract description 8
- 230000014616 translation Effects 0.000 title claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 230000009759 skin aging Effects 0.000 claims abstract description 10
- 230000037303 wrinkles Effects 0.000 claims abstract description 9
- 206010051246 Photodermatosis Diseases 0.000 claims abstract description 7
- 230000008845 photoaging Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000007665 sagging Methods 0.000 claims abstract description 5
- 210000003491 skin Anatomy 0.000 claims description 43
- 210000002950 fibroblast Anatomy 0.000 claims description 23
- 230000032683 aging Effects 0.000 claims description 21
- 102000012422 Collagen Type I Human genes 0.000 claims description 18
- 108010022452 Collagen Type I Proteins 0.000 claims description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- 229920002674 hyaluronan Polymers 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 16
- 102000016359 Fibronectins Human genes 0.000 claims description 12
- 108010067306 Fibronectins Proteins 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 229940024606 amino acid Drugs 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 210000004207 dermis Anatomy 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 230000002500 effect on skin Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 210000004927 skin cell Anatomy 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- -1 cyclic polyols Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- 102000001187 Collagen Type III Human genes 0.000 claims description 3
- 108010069502 Collagen Type III Proteins 0.000 claims description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 210000002510 keratinocyte Anatomy 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 150000003141 primary amines Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- CAVKXZMMDNOZJU-UHFFFAOYSA-N Gly-Pro-Ala-Gly-Pro Natural products C1CCC(C(O)=O)N1C(=O)CNC(=O)C(C)NC(=O)C1CCCN1C(=O)CN CAVKXZMMDNOZJU-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000037149 energy metabolism Effects 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000003410 keratolytic agent Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 230000036562 nail growth Effects 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 230000019612 pigmentation Effects 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 210000001626 skin fibroblast Anatomy 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 230000032677 cell aging Effects 0.000 claims 2
- 230000002448 anti-glycating effect Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 230000037394 skin elasticity Effects 0.000 claims 1
- 230000036620 skin dryness Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 29
- 102000008186 Collagen Human genes 0.000 description 18
- 108010035532 Collagen Proteins 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 108010050808 Procollagen Proteins 0.000 description 10
- 230000009758 senescence Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 8
- 239000000835 fiber Substances 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 239000007957 coemulsifier Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710142159 Protein P16 Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本発明はまた、本ペプチドを作用剤として含有する化粧料組成物、ならびに本組成物の細胞外基質タンパク質発現を増加させるための使用に関し、使用することで、シワ、皮膚のたるみおよびしぼみ、ならびに肌の乾燥の出現を遅らせるか、または減少させる。
最後に本発明は、皮膚の加齢サインおよび光加齢サインの出現を遅らせることまたはそれを手当することを意図した美容目的の手入れ法に関する。
【選択図】なし
Description
R1−(AA)n−X1−Pro−X2−Gly−Pro−X3−X4−(AA)p−R2
を有するペプチドが優れた細胞外基質タンパク質合成活性化剤であることを実証した。したがって、このペプチドは、肌の加齢および光加齢に立ち向かうのに適している。
・I型およびIII型コラーゲンの発現を増加させる
・フィブロネクチンの発現を増加させる、
・ヒアルロン酸の発現を増加させる、
・線維芽細胞の老化のサインを減少させる
R1−(AA)n−X1−Pro−X2−Gly−Pro−X3−X4−(AA)p−R2
式中
X1は、グリシンまたはアラニンまたはバリンを表し、
X2は、グリシンまたはアラニンまたはバリンを表し、
X3は、アスパラギンまたはリシンまたはグルタミンを表すか、またはアミノ酸がないことを表し、
X4は、フェニルアラニンまたはチロシンを表すか、またはアミノ酸がないことを表し、
AAは、任意のアミノ酸を表し、ならびにnおよびpは0〜2の整数であり、
R1は、N末端アミノ酸の第一級アミン官能基−NH2を表し、式中2つの水素原子のうち1つは、飽和もしくは不飽和のC1〜C30アルキル鎖、またはアシル基(R−CO−)(式中、R基は、飽和もしくは不飽和のC1〜C30アルキル鎖、好ましくはメチルであり)、またはベンゾイル型、トシル型、もしくはベンジルオキシカルボニル型の芳香族基のいずれかで置換可能であり、
R2は、C末端アミノ酸のカルボキシル官能基のヒドロキシル基−OHを表し、式中、水素原子は、C1〜C30アルキル鎖で置換可能であるか、またはNH2、NHY、もしくはNYY基(式中、Yは、C1〜C4アルキル鎖を表し)を表し、
一般式(I)の上記配列は、5〜11個のアミノ酸残基からなり、塩の形を取ることができる。
(配列番号1):Ala−Pro−Ala−Gly−Pro−NH2
(配列番号2):Val−Pro−Ala−Gly−Pro
(配列番号3):Val−Pro−Gly−Gly−Pro−NH2
(配列番号4):Gly−Pro−Ala−Gly−Pro
(配列番号5):Gly−Pro−Ala−Gly−Pro−NH2
(配列番号6):Lys−Gly−Ala−Pro−Gly−GLy−Pro−Asn−Tyr−NH2
・少なくとも1種のシトクロムc活性化化合物、および/または
・少なくとも1種の水和化化合物(アクアポリン活性化化合物など)および/または
・少なくとも1種のサーチュイン活性化化合物、および/または
・少なくとも1種の細胞接着増加化合物、および/または
・基質タンパク質(コラーゲン、フィブロネクチン、ラミニン、グリコサミノグリカンなど)の産生を増加させる少なくとも1種の化合物、および/または
・少なくとも1種のプロテアソーム活性調節化合物、および/または
・少なくとも1種の概日リズム調節化合物、および/または
・少なくとも1種のHSPタンパク質調節化合物、および/または
・少なくとも1種の細胞エネルギー増加化合物、および/または
・少なくとも1種の肌色素沈着調節化合物、および/または
・少なくとも1種の補酵素Q10活性化化合物、および/または
・バリア機能を改善する少なくとも1種の化合物(トランスグルタミナーゼまたはHMG−CoAレダクターゼ活性化化合物など)、および/または
・少なくとも1種のミトコンドリア保護化合物。
Claims (15)
- 下記一般式(I):
R1−(AA)n−X1−Pro−X2−Gly−Pro−X3−X4−(AA)p−R2
式中
X1は、グリシンまたはアラニンまたはバリンを表し、
X2は、グリシンまたはアラニンまたはバリンを表し、
X3は、アスパラギンまたはリシンまたはグルタミンを表すか、またはアミノ酸がないことを表し、
X4は、フェニルアラニンまたはチロシンを表すか、またはアミノ酸がないことを表し、
AAは、任意のアミノ酸を表し、ならびにnおよびpは0〜2の整数であり、
R1は、該N末端アミノ酸の該第一級アミン官能基−NH2を表し、式中、該2個の水素原子のうち1個は、飽和もしくは不飽和のC1〜C30アルキル鎖、またはアシル基(R−CO−)(式中、該R基は、飽和もしくは不飽和のC1〜C30アルキル鎖、好ましくはメチルであり)、またはベンゾイル型、トシル型、もしくはベンジルオキシカルボニル型の芳香族基のいずれかで置換可能であり、
R2は、該C末端アミノ酸の該カルボキシル官能基の該ヒドロキシル基−OHを表し、式中、該水素原子は、C1〜C30アルキル鎖で置換可能であるか、またはNH2、NHY、もしくはNYY基(式中、Yは、C1〜C4アルキル鎖を表し)を表す、
のペプチドであって、
一般式(I)の該配列は、5〜11個のアミノ酸残基からなり、塩の形を取ることができ、以下の配列:
(配列番号1):Ala−Pro−Ala−Gly−Pro−NH2
(配列番号2):Val−Pro−Ala−Gly−Pro
(配列番号3):Val−Pro−Gly−Gly−Pro−NH2
(配列番号4):Gly−Pro−Ala−Gly−Pro
(配列番号5):Gly−Pro−Ala−Gly−Pro−NH2
(配列番号6):Lys−Gly−Ala−Pro−Gly−Gly−Pro−Asn−Tyr−NH2
のうちの1つに相当することを特徴とするペプチド。 - 前記配列番号4の配列または前記配列番号5の配列に相当することを特徴とする、請求項1に記載のペプチド。
- 1種以上の生理学的に適切な溶媒、例えば、水、グリセロール、エタノール、プロパンジオール、ブチレングリコール、ジプロピレングリコール、エトキシ化またはプロポキシ化ジグリコール、環状ポリオール、またはこれらの溶媒の任意の混合物に対して可溶性であることを特徴とする、請求項1または2に記載のペプチド。
- 生理学的に適切な媒体中に、請求項1から3のうち1項に定義されるとおりのペプチドのうち少なくとも1種を肌の細胞外基質タンパク質合成を活性化させる作用剤として含有する、化粧料用組成物。
- 前記ペプチドは、前記組成物の最終的な全重量に対して、0.0005〜500mg/kg、好ましくは0.01〜5mg/kgの濃度で該組成物中に存在することを特徴とする、請求項4に記載の組成物。
- 局所使用を意図したものであることを特徴とする、請求項4または5に記載の組成物。
- さらに少なくとも1種の他の作用剤を含有することを特徴とする、請求項4から6のいずれか1項に記載の組成物。
- 前記他の作用剤は、再生剤、抗加齢剤、抗シワ剤、鎮静剤、抗フリーラジカル剤、抗糖化剤、水和剤、抗細菌剤、抗真菌剤、角質溶解剤、筋肉弛緩剤、角質除去剤、引き締め剤、真皮の巨大分子の合成またはエネルギー代謝または微小循環または爪成長または髪成長の刺激剤、表皮の分化または色素沈着の調節剤、メタロプロテイナーゼ阻害剤、日焼け止め、および太陽光フィルターから選択されることを特徴とする、請求項7に記載の組成物。
- 肌細胞による細胞外基質タンパク質合成を増加させるための、請求項1から3のうち1項に定義されるとおりのペプチドを作用剤として生理学的に適切な媒体に含有する組成物の美容目的の使用。
- 線維芽細胞によるI型コラーゲン、III型コラーゲン、およびフィブロネクチンの合成を増加させるための、請求項1から3のうち1項に定義されるとおりのペプチドを作用剤として生理学的に適切な媒体に含有する組成物の美容目的の使用。
- 真皮密度および肌の弾力を向上させるための、ならびに顔の造作のたるみ、真皮のしぼみ、肌が薄くなること、アトニー、細かいスジ、および深いシワの発生を遅らせるか減少させるための、請求項4から8のいずれか1項に記載の組成物の美容目的の使用。
- 肌線維芽細胞およびケラチン生成細胞によるヒアルロン酸発現を増加させるための、請求項1から3のうち1項に定義されるとおりのペプチドを作用剤として生理学的に適切な媒体に含有する組成物の美容目的の使用。
- 肌の全ての層の能力を増加させることで、保水力を高め、加齢による肌の乾燥を遅らせるか減少させるための、請求項4から8のいずれか1項に記載の組成物の美容目的の使用。
- 肌細胞の老化の現れを遅らせるか肌細胞の老化を減少させるための、請求項1から3のうち1項に定義されるとおりのペプチドを作用剤として生理学的に適切な媒体に含有する組成物の美容目的の使用。
- 請求項4から8のうち1項に定義されるとおりの組成物を、手当すべき肌に局所的に使用することを特徴とする、皮膚の加齢サインおよび光加齢サインを遅らせるおよび/または手当することを意図した美容目的の手当法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1100497A FR2971784B1 (fr) | 2011-02-18 | 2011-02-18 | Nouveaux peptides activateurs de la synthese des proteines de la matrice extracellulaire et compositions cosmetiques les comprenant |
FR1100497 | 2011-02-18 | ||
PCT/FR2012/000064 WO2012140331A1 (fr) | 2011-02-18 | 2012-02-17 | Nouveaux peptides activateurs de la synthese des proteines de la matrice extracellulaire et compositions cosmetiques les comprenant |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014510052A true JP2014510052A (ja) | 2014-04-24 |
JP6044902B2 JP6044902B2 (ja) | 2016-12-14 |
Family
ID=44060491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013553980A Expired - Fee Related JP6044902B2 (ja) | 2011-02-18 | 2012-02-17 | 細胞外基質タンパク質合成を活性化する新規ペプチドおよびそれを含有する化粧料組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8809276B2 (ja) |
EP (1) | EP2675825B1 (ja) |
JP (1) | JP6044902B2 (ja) |
KR (1) | KR102012527B1 (ja) |
CN (1) | CN103582649B (ja) |
ES (1) | ES2540454T3 (ja) |
FR (1) | FR2971784B1 (ja) |
HK (1) | HK1194397A1 (ja) |
WO (1) | WO2012140331A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180101359A (ko) | 2016-01-18 | 2018-09-12 | 코스메드 파마소티컬 씨오 쩜 엘티디 | 콜라겐 화장품 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104072582B (zh) * | 2013-03-27 | 2020-07-28 | 乐敦制药株式会社 | 新型肽 |
JP6336781B2 (ja) * | 2013-03-27 | 2018-06-06 | ロート製薬株式会社 | 新規ペプチド |
JP6319911B2 (ja) * | 2013-03-29 | 2018-05-09 | 国立大学法人大阪大学 | 抗老化作用を有するペプチドおよびその利用 |
FR3062853A1 (fr) * | 2017-02-14 | 2018-08-17 | Laboratoire Shigeta | Utilisation de 2,5-dicetopiperazines en tant qu’agents cosmetiques |
EP3831358A1 (en) * | 2019-12-04 | 2021-06-09 | Lipotrue, S.L. | Peptides and compositions for use in cosmetics and medicine |
CN115066252A (zh) * | 2019-12-27 | 2022-09-16 | 三得利控股株式会社 | 含有肽的组合物、其生产方法以及肽的用途 |
CN114010526B (zh) * | 2021-12-01 | 2024-07-26 | 宇肽生物(东莞)有限公司 | 一种抗衰多肽组合物及其应用 |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
CN115947790B (zh) * | 2022-11-15 | 2023-06-06 | 诺赛联合(北京)生物医学科技有限公司 | 成纤维细胞外基质制备的三型胶原蛋白组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5618948A (en) * | 1979-07-24 | 1981-02-23 | Ajinomoto Co Inc | Peptide derivative |
JPS604158A (ja) * | 1983-05-16 | 1985-01-10 | サントル・ナシオナル・ド・ラ・ルシエルシユ・シア−ンテイフイク・(セ・エヌ・エ−ル・エス) | ペプチド又はアミノ酸の水溶性アシル化誘導体、その製造方法及び施用方法 |
JPH11513363A (ja) * | 1995-09-15 | 1999-11-16 | レゾリューション・ファーマスーティカルズ・インコーポレーテッド | 受容体非介在性イメージング剤 |
JP2005501220A (ja) * | 2000-12-19 | 2005-01-13 | パラチン テクノロジーズ インク. | ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別 |
US20070054298A1 (en) * | 2005-08-12 | 2007-03-08 | Kent Kirshenbaum | Methods for enzyme-mediated coupling of oligomers |
WO2007087131A2 (en) * | 2006-01-05 | 2007-08-02 | The Johns Hopkins University | Peptide prodrugs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940971B1 (fr) * | 2009-01-09 | 2011-02-18 | Isp Investments Inc | Nouveaux peptides anti-age et composition cosmetique et/ou pharmaceutique les contenant |
-
2011
- 2011-02-18 FR FR1100497A patent/FR2971784B1/fr not_active Expired - Fee Related
-
2012
- 2012-02-17 CN CN201280009431.3A patent/CN103582649B/zh active Active
- 2012-02-17 ES ES12709676.6T patent/ES2540454T3/es active Active
- 2012-02-17 WO PCT/FR2012/000064 patent/WO2012140331A1/fr active Application Filing
- 2012-02-17 EP EP20120709676 patent/EP2675825B1/fr active Active
- 2012-02-17 KR KR1020137024608A patent/KR102012527B1/ko active IP Right Grant
- 2012-02-17 JP JP2013553980A patent/JP6044902B2/ja not_active Expired - Fee Related
- 2012-02-17 US US13/984,568 patent/US8809276B2/en active Active
-
2014
- 2014-07-31 HK HK14107863.3A patent/HK1194397A1/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5618948A (en) * | 1979-07-24 | 1981-02-23 | Ajinomoto Co Inc | Peptide derivative |
JPS604158A (ja) * | 1983-05-16 | 1985-01-10 | サントル・ナシオナル・ド・ラ・ルシエルシユ・シア−ンテイフイク・(セ・エヌ・エ−ル・エス) | ペプチド又はアミノ酸の水溶性アシル化誘導体、その製造方法及び施用方法 |
JPH11513363A (ja) * | 1995-09-15 | 1999-11-16 | レゾリューション・ファーマスーティカルズ・インコーポレーテッド | 受容体非介在性イメージング剤 |
JP2005501220A (ja) * | 2000-12-19 | 2005-01-13 | パラチン テクノロジーズ インク. | ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別 |
US20070054298A1 (en) * | 2005-08-12 | 2007-03-08 | Kent Kirshenbaum | Methods for enzyme-mediated coupling of oligomers |
WO2007087131A2 (en) * | 2006-01-05 | 2007-08-02 | The Johns Hopkins University | Peptide prodrugs |
Non-Patent Citations (1)
Title |
---|
JPN6016000835; Eur. J. Biochem. Vol. 259, 1999, pp. 275-280 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180101359A (ko) | 2016-01-18 | 2018-09-12 | 코스메드 파마소티컬 씨오 쩜 엘티디 | 콜라겐 화장품 |
Also Published As
Publication number | Publication date |
---|---|
FR2971784B1 (fr) | 2015-01-02 |
EP2675825B1 (fr) | 2015-04-29 |
EP2675825A1 (fr) | 2013-12-25 |
FR2971784A1 (fr) | 2012-08-24 |
US8809276B2 (en) | 2014-08-19 |
CN103582649B (zh) | 2016-06-01 |
CN103582649A (zh) | 2014-02-12 |
KR102012527B1 (ko) | 2019-08-20 |
JP6044902B2 (ja) | 2016-12-14 |
US20140044655A1 (en) | 2014-02-13 |
ES2540454T3 (es) | 2015-07-09 |
HK1194397A1 (zh) | 2014-10-17 |
KR20140096989A (ko) | 2014-08-06 |
WO2012140331A1 (fr) | 2012-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6044902B2 (ja) | 細胞外基質タンパク質合成を活性化する新規ペプチドおよびそれを含有する化粧料組成物 | |
JP5938787B2 (ja) | 新規サーチュイン6活性化ペプチド及びそれを含有する化粧料または医薬組成物 | |
JP5647995B2 (ja) | 新規な抗老化ペプチド、並びにそれを含む化粧品及び/または製薬組成物 | |
JP5647994B2 (ja) | 新規な抗老化ペプチド、並びにそれを含む化粧品及び/または製薬組成物 | |
JP2018537455A (ja) | 低分子rnaオニユリ抽出物を含む局所組成物および加齢に関する皮膚の徴候を低減するための美容ケア方法 | |
JP6282582B2 (ja) | 皮膚老化の徴候を低減または遅延させるための、ジンゲロンまたはその誘導体の使用 | |
JP5858482B2 (ja) | スルビビンを調節する新規の抗加齢ペプチドおよびこれを含む組成物 | |
CN107405278B (zh) | 序列为his-d-trp-ala-trp-d-phe-lys-nh2的肽用于减少或延缓细胞衰老的出现和皮肤老化的迹象的用途 | |
JP6065236B2 (ja) | タンパク質trf2の調節物質である新規ペプチドおよびそれを含む組成物 | |
JP6179771B2 (ja) | 新規デルマトポンチン活性化ペプチド及びそれを包含する化粧品組成物 | |
JP5827958B2 (ja) | 新規カスパーゼ−14活性化ペプチドおよびそれを含む組成物 | |
FR2940971A1 (fr) | Nouveaux peptides anti-age et composition cosmetique et/ou pharmaceutique les contenant | |
CN105461784A (zh) | 一种抗衰老肽化合物、其组合物及应用 | |
FR2955113A1 (fr) | Nouveaux peptides modulateurs de la survivine et compositions les comprenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160419 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160610 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161004 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161104 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6044902 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |